Detalhe da pesquisa
1.
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643491
2.
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Blood
; 143(2): 152-165, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37832030
3.
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.
Hematol Oncol
; 42(1): e3240, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38050405
4.
Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.
Br J Haematol
; 197(6): 679-690, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362554
5.
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Br J Haematol
; 197(5): 558-572, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191541
6.
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Br J Haematol
; 196(4): 892-901, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34761389
7.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Br J Haematol
; 198(3): 492-502, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35485402
8.
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Value Health
; 25(6): 1010-1017, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667774
9.
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Curr Oncol Rep
; 24(11): 1477-1488, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696020
10.
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Br J Haematol
; 194(3): 508-517, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618434
11.
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Br J Haematol
; 193(1): 63-71, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926420
12.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med
; 379(18): 1711-1721, 2018 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380386
13.
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
BMC Cancer
; 21(1): 851, 2021 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301221
14.
Tackling PD1i resistance in Hodgkin lymphoma.
Blood
; 142(16): 1333-1334, 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37856096
15.
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Haematologica
; 105(7): 1914-1924, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31488560
16.
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy.
Eur J Haematol
; 105(4): 476-483, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544294
17.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(5): 649-662, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948276
18.
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Cancer
; 125(1): 99-108, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30332497
19.
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Br J Haematol
; 184(4): 547-557, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30467838
20.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Br J Haematol
; 187(2): 185-194, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222719